col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


18 Ergebisse       Seite 1

 [1] 
Springer-Verlag: Clinical Pharmacokinetics
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2026―Mrz―31 Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve Huixia Zhang, Weifeng Tang, Samuel Sadow, Roberta Baronio, Antonella Nadia Tullio, Lauren Hirao, et al. (+6)
2 [GO] 2025―Apr―22 Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19 Darren M. Roberts, Xin Liu, Suzanne L. Parker, Andrew Burke, Jenny Peek, Jane E. Carland, et al. (+13)
3 [GO] 2024―Nov―20 Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study Toru Ishibashi, Ryosuke Shimizu, Ryuji Kubota
4 [GO] 2024―Nov―15 Pharmacokinetics of Enteral Lormetazepam in Mechanically Ventilated ICU Patients with COVID-19: An Adjunct Sedative Study Jos L. M. L. le Noble, Kimberly N. Shudofsky, Norbert Foudraine, Nieko Punt, Paddy K. J. Janssen
5 [GO] 2024―Jun―28 Correction to: Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19 Tim J. L. Smeets, Abraham J. Valkenburg, Mathieu van der Jagt, Birgit C. P. Koch, Henrik Endeman, Diederik A. M. P. J. Gommers, et al. (+2)
6 [GO] 2023―Apr―25 Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19 Paweł Piwowarczyk, Marta Szczukocka, Wojciech Cios, Paulina Okuńska, Grzegorz Raszewski, Michał Borys, et al. (+2)
7 [GO] 2022―Aug―30 Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review María Patricia Hernández-Mitre, Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, et al. (+6)
8 [GO] 2022―Jul―29 Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy Maor Wanounou, Yoseph Caraco, René H. Levy, Meir Bialer, Emilio Perucca
9 [GO] 2022―Jul―23 Could Fluvoxamine Dose De-escalation Increase Treatment Compliance Without Sacrificing Efficacy in COVID-19 Patients? Robert Marcec, Robert Likic
10 [GO] 2022―Apr―10 Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19 Tim J. L. Smeets, Abraham J. Valkenburg, Mathieu van der Jagt, Birgit C. P. Koch, Henrik Endeman, Diederik A. M. P. J. Gommers, et al. (+2)
11 [GO] 2021―Dez―11 Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 Elizabeth Leung, Ryan L. Crass, Sarah C. J. Jorgensen, Sumit Raybardhan, Bradley J. Langford, W. Justin Moore, Nathaniel J. Rhodes
12 [GO] 2021―Okt―11 Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study Dirk Jan A. R. Moes, David J. van Westerloo, Sandra M. Arend, Jesse J. Swen, Annick de Vries, Henk-Jan Guchelaar, et al. (+4)
13 [GO] 2021―Apr―17 Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6” Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, Filippo Givone, Martina Fabris, Jessica Biasizzo, et al. (+2)
14 [GO] 2021―Apr―17 Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6” Dario Cattaneo, Mario Corbellino, Valeria Cozzi, Marta Fusi, Cristina Gervasoni
15 [GO] 2021―Mrz―30 Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor Rita Humeniuk, Anita Mathias, Brian J. Kirby, Justin D. Lutz, Huyen Cao, Anu Osinusi, et al. (+6)
16 [GO] 2020―Aug―27 Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, Filippo Givone, Martina Fabris, Jessica Biasizzo, et al. (+2)
17 [GO] 2020―Jul―28 Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents Markus Zeitlinger, Birgit C. P. Koch, Roger Bruggemann, Pieter De Cock, Timothy Felton, Maya Hites, et al. (+12)
18 [GO] 2020―Apr―18 Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties Cornelis Smit, Mariska Y. M. Peeters, John N. van den Anker, Catherijne A. J. Knibbe
 [1] 

18 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec